piperacillin has been researched along with Diabetic Feet in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Sivashanmugam, K; Srivastava, P | 1 |
| Demetriou, M; Maltezos, E; Panagopoulos, P; Panopoulou, M; Papanas, N | 1 |
| Lagan, KM; McArdle, CD; McDowell, DA | 1 |
| Kumar, A; Shahi, SK; Singh, VK | 1 |
| Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
| Lipsky, BA; Mutluoglu, M | 1 |
| Deshpande, MM | 1 |
| Esposito, S; Felaco, FM; Fiore, M; Ianniello, F; Leone, S; Noviello, S; Romagnoli, F; Sarli, E | 1 |
| Bayram, H; Dalay, C; Dalkiran, A; Saltoglu, N; Sert, M; Tasova, Y; Tetiker, T | 1 |
| Carmeli, Y; Jansen, JP; Kumar, R | 1 |
| Dwivedi, A; Gupta, SK; Pratyush, DD; Rai, M; Singh, SK; Tiwari, S | 1 |
| Ay, H; Hatipoglu, M; Mutluoglu, M; Onem, Y; Turhan, V; Uzun, G | 1 |
| Ay, H; Önem, Y; Salihoğlu, M; Turhan, V; Ulcay, A; Uzun, G | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Esposito, S; Ianniello, F; Leone, S; Maiello, A; Marvaso, A; Noviello, S; Petronella, P | 1 |
| Boghossian, J; Caputo, W; Dana, A; Gray, S; Harkless, L; Pollak, R; Wu, D | 1 |
| Dittrich, P; Hoffmann, C; Kerl, H; Krause, R; Legat, FJ; Salmhofer, W; Scholz, S; Tscherpel, J; Tscherpel, T; Zenahlik, P | 1 |
| Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
| Al-Ebous, AD; Al-Jahmi, M; Al-Zuriqat, AN; Hiasat, B; Sarayrah, M | 1 |
| Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
| Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Diepersloot, RJ; Hoekstra, JB; Hoynck van Papendrecht, AA; van Kraaij, MG; Veldkamp, KE; Zeillemaker, AM | 1 |
7 trial(s) available for piperacillin and Diabetic Feet
| Article | Year |
|---|---|
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Female; Hospitals, University; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sulbactam; Time Factors; Vancomycin; Wound Infection | 2005 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
Management of diabetic foot in a Jordanian hospital.
Topics: Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Ceftazidime; Chemotherapy, Adjuvant; Debridement; Diabetic Foot; Drug Combinations; Drug Monitoring; Humans; Imipenem; Kidney Diseases; Length of Stay; Lincomycin; Metronidazole; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Severity of Illness Index; Treatment Outcome; Wound Healing; Wound Infection | 2005 |
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
16 other study(ies) available for piperacillin and Diabetic Feet
| Article | Year |
|---|---|
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Antibiotic Resistance in Diabetic Foot Soft Tissue Infections: A Series From Greece.
Topics: Aged; Anti-Bacterial Agents; Biological Availability; Diabetic Foot; Drug Resistance, Microbial; Female; Greece; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Soft Tissue Infections | 2017 |
Effects of pH on the Antibiotic Resistance of Bacteria Recovered from Diabetic Foot Ulcer Fluid
Topics: Anti-Bacterial Agents; Diabetic Foot; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Wound Healing | 2018 |
Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clindamycin; Diabetic Foot; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Multiplex Polymerase Chain Reaction; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Structural Homology, Protein; Structure-Activity Relationship | 2013 |
Non-surgical treatment of diabetic foot osteomyelitis.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Diabetes Mellitus, Type 2; Diabetic Foot; Humans; Male; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
Diabetic foot ulcer: assessment and management.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Humans; Piperacillin | 2008 |
Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Italy; Male; Middle Aged; Outpatient Clinics, Hospital; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Staphylococcal Infections; Young Adult | 2008 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
Microbiological and clinical characteristics of diabetic foot infections in northern India.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Diabetic Foot; Female; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies | 2012 |
Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection.
Topics: Aged; Anti-Bacterial Agents; Diabetes Mellitus, Type 2; Diabetic Foot; Fever; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia | 2013 |
Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection.
Topics: Anti-Bacterial Agents; Daptomycin; Diabetes Mellitus, Type 2; Diabetic Foot; Hearing Loss, Sudden; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2013 |
[Outpatient parenteral antibiotic therapy (OPAT) of diabetic foot infections with piperacillin/tazobactam].
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Injections; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2002 |
Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Diabetic Foot; Extracellular Fluid; Female; Humans; Inflammation; Male; Microdialysis; Middle Aged; Penicillanic Acid; Piperacillin; Soft Tissue Infections; Tazobactam | 2005 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Piperacillin/tazobactam therapy for diabetic foot infection.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Foot; Drug Combinations; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcal Infections; Tazobactam | 1998 |